QNRX · Quoin Pharmaceuticals Ltd. · Documents
$4.05
+0.04 (+1.00%)
At close · Oct 27
Return incl. dividend (before tax)
Q4 2023 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based upon the Company's current business plans and cash, cash equivalents, and investments on hand, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of the filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
Market Cap
$19.26M
Shares
4.80M
Volume · Oct 27
1522
Avg daily vol (3M)
536.56K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Quoin Pharmaceuticals Ltd. announced a peer-reviewed QRX003 case report in Dermatology and Therapy; four of six participants completing 12 weeks achieved a 1-grade or greater improvement in Investigator Global Assessment. | 2026-10-20 | — | |
| 8-K | Quoin Pharmaceuticals Ltd. announced European Medicines Agency Orphan Drug Designation for QRX003 in Peeling Skin Syndrome, providing potential 10 years of market exclusivity if approved. It plans a first clinical study before year end. | 2026-10-14 | — | |
| DEF 14A | Quoin Pharmaceuticals Ltd. will ask shareholders on November 12, 2026 to raise private placement warrant holders’ ownership and voting caps from 4.99% to up to 9.99%, and to approve adjournment authority if votes are insufficient; the board recommends “FOR” both. | 2026-10-02 | 2026-11-12 | |
| 8-K | Quoin Pharmaceuticals Ltd. said the FDA granted Fast Track Designation to QRX003 for Peeling Skin Syndrome on Sept. 22, 2026, its second designation after Netherton Syndrome. It expects a Phase 2/3 study in the second half of 2026. | 2026-09-22 | — | |
| PRE 14A | Quoin Pharmaceuticals Ltd. will ask shareholders on November 12, 2026 to raise private-placement investors’ ownership and voting caps from 4.99% to any percentage not exceeding 9.99%. The board recommends approval and an adjournment if votes are insufficient. | 2026-09-22 | 2026-11-12 | |
| S-3 | — | 2026-09-18 | — | |
| 8-K | — | 2026-09-10 | 2026-09-08 | |
| 8-K | — | 2026-08-28 | 2026-08-27 | |
| 8-K | — | 2026-08-20 | — | |
| 8-K | — | 2026-08-14 | — | |
| 10-Q | — | 2026-08-14 | 2026-06-30 | |
| DEF 14A | — | 2026-07-16 | 2026-08-20 | |
| ARS | — | 2026-07-16 | 2025-12-31 | |
| PRE 14A | — | 2026-07-06 | 2026-08-20 | |
| 8-K | — | 2026-06-23 | — | |
| 8-K | — | 2026-06-04 | — | |
| 8-K | — | 2026-05-07 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| 8-K | — | 2026-03-26 | — | |
| 10-K | — | 2026-03-26 | 2025-12-31 | |
| 8-K | — | 2026-03-11 | — | |
| 8-K | — | 2026-01-20 | — | |
| 8-K | — | 2025-11-17 | 2025-11-14 | |
| 8-K | — | 2025-11-12 | 2025-11-11 | |
| S-3 | — | 2025-11-07 | — | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-11-06 | — | |
| 8-K | — | 2025-10-21 | — | |
| 8-K | — | 2025-10-15 | 2025-10-10 | |
| 8-K | — | 2025-08-27 | 2025-08-21 | |
| 8-K | — | 2025-08-21 | 2025-08-15 | |
| 10-Q | — | 2025-08-07 | 2025-06-30 | |
| 8-K | — | 2025-08-07 | — | |
| DEF 14A | — | 2025-07-17 | 2025-08-21 | |
| ARS | — | 2025-07-17 | 2024-12-31 | |
| 8-K | — | 2025-07-08 | 2025-07-03 | |
| PRE 14A | — | 2025-07-07 | 2025-08-21 | |
| 8-K | — | 2025-06-25 | 2025-06-24 | |
| 8-K | — | 2025-06-20 | 2025-06-18 | |
| 8-K | — | 2025-06-04 | 2025-05-29 | |
| 8-K | — | 2025-05-23 | 2025-05-22 | |
| 8-K | — | 2025-05-21 | 2025-05-20 | |
| 8-K | — | 2025-05-14 | 2025-05-13 | |
| 10-Q | — | 2025-05-13 | 2025-03-31 | |
| 8-K | — | 2025-04-30 | 2025-04-29 | |
| 8-K | — | 2025-04-04 | — | |
| 8-K | — | 2025-04-04 | — | |
| 8-K | — | 2025-04-02 | — | |
| 8-K | — | 2025-03-20 | 2025-03-18 | |
| 10-K | — | 2025-03-13 | 2024-12-31 |
Showing 1–50 of 181 filings